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Abstract
Background: The effect of glucagon-like peptide-1(GLP-1) receptor agonists on heart failure remains uncertain. We
therefore conducted a systematic review to assess the possible impact of GLP-1 agonists on heart failure or
hospitalization for heart failure in patients with type 2 diabetes.
Methods: We searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL) and
ClinicalTrials.gov to identify randomized controlled trials (RCTs) and observational studies that addressed the
effect of GLP-1 receptor agonists in adults with type 2 diabetes, and explicitly reported heart failure or hospitalization
for heart failure. Two paired reviewers screened reports, collected data, and assessed the risk of bias. We pooled data
from RCTs and observational studies separately, and used the GRADE approach to rate the quality of evidence.
Results: We identified 25 studies that were eligible for our review; 21 RCTs (n = 18,270) and 4 observational
studies (n = 111,029). Low quality evidence from 20 RCTs suggested, if anything, a lower incidence of heart failure
between GLP-1 agonists versus control (17/7,441 vs. 19/4,317; odds ratio (OR) 0.62, 95 % confidence interval (CI)
0.31 to 1.22; risk difference (RD) 19 fewer, 95 % CI 34 fewer to 11 more per 1000 over 5 years). Three cohort
studies comparing GLP-1 agonists to alternative agents provided very low quality evidence that GLP-1 agonists
do not increase the incidence of heart failure. One RCT provided moderate quality evidence that GLP-1 agonists
were not associated with hospitalization for heart failure (lixisenatide vs placebo: 122/3,034 vs. 127/3,034; adjusted
hazard ratio 0.96, 95 % CI 0.75 to 1.23; RD 4 fewer, 95 % CI 25 fewer to 23 more per 1000 over 5 years) and a
case–control study provided very low quality evidence also suggesting no association (GLP-1 agonists vs. other
anti-hyperglycemic drugs: 1118 cases and 17,626 controls, adjusted OR 0.67, 95 % CI 0.32 to 1.42).
Conclusions: The current evidence suggests that GLP-1 agonists do not increase the risk of heart failure or
hospitalization for heart failure among patients with type 2 diabetes.
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Background
Glucagon-like peptide-1 (GLP-1) receptor agonists are a
relatively new class of incretin-based agents for the treat-
ment of type 2 diabetes mellitus that lower blood glucose
[1, 2], reduce body weight [3], and possibly reduce cardio-
vascular risk compared to placebo [4, 5]. The American
Diabetes Association and the European Association for
the Study of Diabetes recommend GLP-1 agonists as a
second-line treatment option for type 2 diabetes [6].
In 2014, the US Food and Drug Administration raised
concerns regarding heart failure risk with one dipepti-
dyl peptidase-4 (DPP-4) inhibitor, saxagliptin [7]. These
concerns followed publication of studies that reported
increased risk of hospitalization for heart failure in pa-
tients using DPP-4 inhibitors [8–10]. These observa-
tions raise the possibility that GLP-1 agonists, which
share a similar pharmacological mechanism with DPP-4
inhibitors, might also cause heart failure.
Animal studies have shown that the GLP-1 agonist
liraglutide can activate cytoprotective pathways in the
heart, and improve outcomes after experimental myo-
cardial infarction in mice [11]. Early clinical studies also
suggested that GLP-1 agonists have positive effects on
cardiovascular biomarkers, such as high-sensitivity C-
reactive protein and plasminogen activator inhibitor-1
[12, 13], and improve regional and overall left ventricu-
lar function in patients with acute myocardial infarction
and severe systolic dysfunction after successful primary
angioplasty [14].
Clinical trial results often, however, prove inconsistent
with laboratory and surrogate outcome studies, and
emerging randomized trials and observational studies
have, reported inconsistent results [15–19]. We there-
fore undertook a systematic review to address the effect
of GLP-1 agonists on heart failure or hospitalization for
heart failure in patients with type 2 diabetes.
Methods
We followed the PRISMA and MOOSE guidelines for con-
ducting and reporting systematic reviews and meta-analyses
of randomized controlled trials (RCTs) and observational
studies [20, 21].
Data sources and search strategy
We searched MEDLINE, EMBASE, and the Cochrane
Central Register of Controlled Trials (CENTRAL) from
inception to 25 June, 2015. We used both MeSH and
free text terms to identify relevant articles. An informa-
tion expert (DP) developed each database-specific search
strategy (Additional file 1). We also searched Clinical-
Trials.gov as well as conference abstracts published by
the American Diabetes Association, European Association
for the Study of Diabetes, and European Society of Cardi-
ology for additional eligible studies and trial information.
Eligibility criteria
We included RCTs, cohort studies, or case–control
studies that compared GLP-1 agonists against placebo,
lifestyle modification, or active anti-hyperglycemic medica-
tion in adult type 2 diabetes patients, reported ≥ 12 weeks
follow-up data (not applicable to case–control studies),
and explicitly reported the outcome of heart failure or
hospitalization for heart failure.
Study selection
Paired reviewers, trained in research methods, inde-
pendently screened titles/abstracts and then full texts
for eligibility, assessed risk of bias, and collected data
from each included study, using pilot-tested standard-
ized forms with corresponding detailed instructions.
Any disagreement between the two reviewers was re-
solved through discussion or adjudication by a third re-
viewer (XS).
Risk of bias and quality of evidence assessment
We assessed the risk of bias of RCTs according to modi-
fied version of the Cochrane Collaboration’s tool [22, 23]
in which the response options are "probably yes" and
"probably no" instead of "unclear"; the approach has
shown to be reliable and valid for blinding [24]. The
items include randomization sequence generation; allo-
cation concealment; blinding of participants, caregivers,
outcome assessors (i.e., heart failure or hospitalization
for heart failure), and outcome adjudicators; prognostic
balance between treatment groups; and incomplete out-
come data.
We used a modified version of the Newcastle – Ottawa
Quality Assessment Scale [25–27] for assessing risk of
bias of observational studies. Specifically, we removed two
items “representativeness of the exposed cohort” and “was
follow-up long enough for outcomes to occur” that we
judge related to applicability, and added two items - ascer-
tainment of type 2 diabetes and adjustment for potential
confounding factors. We planned to assess for risk of pub-
lication bias, but were unable to do so due to low power
of the relevant tests in the presence of low events rates.
We rated the quality of evidence for heart failure and
hospitalization for heart failure as high, moderate, low,
or very low using the Grading of Recommendations As-
sessment, Development and Evaluation (GRADE) meth-
odology [28–34].
Data extraction
We collected the following information from each eli-
gible studies: study characteristics (e.g., author name,
year of publication, study design, sample size, length
of follow-up), patient characteristics (e.g., gender, age,
diabetes duration, body mass index (BMI), baseline
HbA1c level), interventions (e.g., details of GLP-1
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agonists therapy and control group), and outcomes
(number of events and patients included for analyses
in each group, as well as adjusted data if available).
For trials with multiple reports, we collated all data
into a single study [35]; for trials with reports both
from ClincialTrials.gov and journal publications, we
carefully checked the data for consistency; for trials
reporting outcome data of multiple follow up points,
we used the data with longest follow up. For observa-
tional studies, we also collected information on data
source, methods used to control confounding, and re-
ported adjustment factors.
Statistical analysis
We analyzed RCTs and observational studies separately.
We did not combine the outcomes of heart failure and
hospitalization for heart failure, as hospitalization for heart
failure is likely more serious and of greater importance to
patients than heart failure not requiring hospitalization.
We assessed statistical heterogeneity with the Cochran
chi-square test and I-squared statistic. We used Peto’s
method to pool data from RCTs [36, 37] using random
effects models and reported pooled Peto odds ratios
(ORs) and associated 95 % confidence intervals (CIs).
We conducted four a priori subgroup analyses to explore
heterogeneity associated with our pooled estimates: (1)
type of control (placebo vs. active treatment), (2) length
of follow up (52 weeks or shorter vs. over 52 weeks), (3)
mode of therapy (GLP-1 agonists monotherapy vs. add-
on/combination therapy), and (4) individual GLP-1 ago-
nists agents (different GLP-1 agonists agents vs. control).
We also carried out sensitivity analyses to explore the
robustness of our findings using different effect mea-
sures, pooling methods, and statistical models.
We pooled adjusted estimates of heart failure from
cohort studies using random effects model due to sig-
nificant variations in the comparison and patient popu-
lations among eligible studies.
Ethics
Ethical approval was not necessary as this study is a Sys-
tematic Review and Meta-Analysis.
Results
Study selection
Our literature search yielded 11,441 reports; 821 were
potentially eligible after title and abstract screening,
and 25 studies proved eligible after full text screening.
These included 21 RCTs involving 18,270 patients from
30 reports [15, 16, 38–65] and four observational stud-
ies [17–19, 66] involving 111,029 patients (three cohort
studies and one nested case–control study) (Fig. 1).
Evidence from randomized controlled trials
RCTs reporting heart failure
Twenty trials reported on heart failure; 18 (80 %) were
multi-center studies, and 18 (90 %) were clearly labeled
as phase III trials. These trials enrolled 46 to 1,091 pa-
tients (total 12,199); the mean age of patients ranged
52.9 to 67.2 years old, mean BMI 25.6 to 33.3 kg/m2,
mean baseline HbA1c 7.6 to 8.5 %, mean FPG 7.1 to
10.0 mmol/L, and mean or median duration of diabetes
was 2.6 to 11.5 years (Table 1). Five used GLP-1 ago-
nists as monotherapy, 15 as add-on or combination
therapy (Table 2). The length of follow-up ranged from
16 to 164 weeks (median 52; 10 trials followed patients
for > 52 weeks).
All the trials reported industry funding; 18 were iden-
tified from ClinicalTrials.gov, of which 12 had no corre-
sponding journal publications. Because of the limited
information provided in the trial registry, we were un-
able to adequately assess the risk of bias for these 12
trials. Additional file 2 presents the details of the as-
sessment for risk of bias. The baseline demographics
and clinical characteristics of patients in each included
trials were generally balanced between groups. The
overall risk bias of eligible RCTs was moderate.
Twenty trials reported 36 heart failure events in
11,758 patients using at least one medication (raw
event rate 0.3 %). The pooling of those trials showed no
statistically significant difference in the risk of heart
failure between GLP-1 agonists treatment and control
(17/7,441 in GLP-1 agonists and 19/4,317 control; OR
0.62, 95 % CI 0.31 to 1.22, I-square = 0 %; risk differ-
ence (RD) 19 fewer, 95 % CI 34 fewer to 11 more per
1000 over 5 years) (Fig. 2). We rated the quality of evi-
dence as low because of risk of bias and imprecision
(Table 3).
Subgroup analysis by type of control (interaction p =
0.79), mode of therapy (interaction p = 0.84) and length
of follow up (interaction p = 0.64) showed no differen-
tial treatment effects (Additional files 3, 4, 5 and 6).
The subgroup analysis of heart failure risk by individual
GLP-1 agonists agents suggested a possibility of differen-
tial treatment effect across individual agents (interaction
p = 0.07), with liraglutide associated with a non-significant
increased risk for heart failure (OR 4.85, 95 % CI 0.75 to
31.36); this finding was however based on a limited num-
ber of events (five in total) and characterized with very
wide confidence interval.
Sensitivity analysis using alternative effect measures,
statistical methods, and analysis models did not show
important changes in pooled effects.
Trials reporting hospitalization for heart failure
The Evaluation of LIXisenatide in Acute Coronary Syn-
drome (ELIXA) trial, designed to assess the cardiovascular
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safety of lixisenatide, reported hospitalization for heart
failure [15, 16] (Table 1). The ELIXA trial randomized
6,068 patients with type 2 diabetes and a recent acute
coronary syndrome to lixisenatide or placebo, with a
median of follow up of 2.1 years. In this trial, 122 pa-
tients were hospitalized for heart failure among 3,034
patients taking lixisenatide (4.0 %) and 127 in 3034 pa-
tients taking placebo (4.2 %), and no statistically signifi-
cant difference was present between the groups (hazard
ratio (HR) 0.96, 95 % CI 0.75 to 1.23; RD 4 fewer, 95 %
CI 25 fewer to 23 more per 1000 over 5 years). The trial
authors' subgroup analysis by type of history of heart
failure showed no differential treatment effects (lixise-
natide vs. placebo: patients with history of heart failure:
HR 0.93, 95%CI 0.66 to 1.30; patients with no history of
heart failure: HR 0.97, 95 % CI 0.67 to 1.40). We rated
the quality of evidence as moderate (Table 3).
Evidence from observational studies
Studies reporting heart failure
Three cohort studies [17, 18, 66] reported heart fail-
ure. Of these, one prospectively designed study [66]
examined exenatide versus basal insulin; the other two
[17, 18] – retrospective in design - assessed GLP-1 ag-
onists versus sulfonylureas, and exenatide or exenatide
plus insulin versus insulin (Tables 4 and 5). The sam-
ple sizes ranged from 882 to 39,225, and length of fol-
low up ranged from 1 to 4 years. The mean age ranged
from 58.28 to 62.5 years, BMI 32.6 to 35.3 kg/m2, and
mean baseline HbA1c 7.9 to 8.9 %.
The three studies used electronic heath records or
claims data for their analyses. Type 2 diabetes patients
were ascertained by specialists in outpatient setting in
the prospective cohort study [66]; the other two retro-
spective cohort study [17, 18] did not explicitly state the
Potentially eligible reports accessed for full text screening (n=821)
Duplicates (n=2749)
Excluded studies (n=787)
Improper study design (n=50)
Inappropriate comparisons (n=121)
Follow-up less than12 weeks (n=11)
Not type 2 diabetes mellitus patients (n=7)
No heart failure outcome clearly and explicitly 
reported (n=596)
Data from a same electronic database (n=2)
Records identified through 
database searches (n=11106)
Studies included in the review (n= 25)
21 RCTs reported in 30 reports (10 journals reports, 19 trial registry reports,
and 1 conference abstract)
4 observational studies (3 cohort studies and 1 nested case-control studies; 3 
journals reports, 1 trial registry report)
Records screened (n=8692)
Records excluded after title and abstract screening 
(n=7871)
Additional records identified from 
ClinicalTrials.gov (n=329),
and conference website (n=6)
Fig. 1 Flow chart of article selection
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ascertainment of type 2 diabetes. None of these studies
mentioned the ascertainment of exposure to GLP-1
agonist agents and other confounding variables. Only
one study [17] demonstrated that outcome of interest
was not present at start of study, and mentioned the
method used to assess the outcome of interest. Two
Table 1 Baseline characteristics of included randomized controlled trials
Study International
study
Number of
countries
involved
Number
of study
sites
Study
phase
Total number
of patients
randomized
Length of
follow up
(weeks)
Male
(n,%)
Mean
age
(years)
Mean BMI
(kg/m2)
Mean
HbA1c
(%)
Mean FPG
(mmol/L)
Mean
diabetes
duration
(years)
Trials reporting heart failure
Inagaki 2012
[38, 39]
No 1 NR III 427 26 290
(67.9)
56.8 26.1 8.5 NR 9.0
NCT00294723
2010 [40, 41]
Yes 2 138 III 746 104 371
(49.7)
53.0 33.1 8.3 9.4 5.4
NCT00318461
2010 [42–44]
Yes 21 170 III 1091 104 635
(58.2)
56.7 31.0 8.4 10.0 7.6
NCT00360334
2009 [45]
No 1 35 III 235 26 160
(68.4)
56.6 NR NR NR 6.0
NCT00614120
2010 [46]
Yes 3 51 III 929 16 514
(55.3)
53.3 25.6 NR NR 7.5
NCT00701935
2013 [47]
Yes 2 17 II 80 26 42
(52.5)
58.1 NR NR NR NR
NCT00838903
2014 [48, 49]
Yes 10 289 III 1049 164 482
(47.6)
54.5 32.6 8.1 9.2 6.0
NCT00838916
2014 [50, 51]
Yes 4 222 III 779 164 418
(56.1)
55.5 33.1 8.3 9.5 8.8
NCT00839527
2014 [52]
Yes 9 358 III 685 164 353
(53.2)
55.2 NR NR NR NR
NCT00849017
2014 [53]
Yes 3 262 III 309 164 166
(55.1)
52.9 NR NR NR NR
NCT00849056
2014 [54]
Yes 6 331 III 310 156 180
(59.8)
55.0 NR NR NR NR
NCT00855439
2015 [55]
No 1 1 NR 46 82 26
(56.5)
53.0 NR NR NR NR
NCT00960661
2013 [56, 57]
Yes 17 108 III 637 30 261
(51.2)
59.5 32.5 8.2 7.1 11.5a
NCT01064687
2015 [58]
Yes 3 89 III 978 26 570
(58.4)
55.7 33.2 8.1 9.0 8.8
NCT01075282
2015 [59]
Yes 20 78 III 810 78 353
(51.3)
56.7 31.6 8.1 9.1 9.1
NCT01126580
2015 [60, 61]
Yes 19 91 III 807 56 353
(43.7)
55.6 33.3 7.6 9.0 2.6
NCT01191268
2014 [62]
Yes 16 101 III 884 52 473
(53.5)
59.4 32.5 8.5 NR 12.7
NCT01512108
2014 [63]
No 1 36 III 363 52 262
(72.8)
59.5 NR 8.1 8.8 NR
NCT01620489
2014 [64]
Yes 6 50 III 277 26 140
(50.5)
67.2 NR NR NR NR
Pratley
2013 [65]
Yes 17 130 III 760 24 362
(48.9)
56.4 32.7 8.3 10.0 8.8
Trials reporting hospitalization for heart failure
Bentley-Lewis
2015 (ELIXA)
[15, 16]
Yes 49 NR III 6068 108b 4207
(69.3)
60.3 30.2 7.7 8.2 9.3
BMI body mass index, FPG fasting plasma glucose, NR not reported
amedian diabetes duration (years); bmedian follow up time (weeks)
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studies [18, 19] used advanced statistical model to con-
trol for the influence of confounding factors. Overall,
the risk of bias associated with these studies was moder-
ate to high (Additional file 7).
All three studies reported raw data, for a total of 2,868
heart failures among 53,292 patients (raw event rate 5.4 %);
two retrospective cohort studies [17, 18] reported adjusted
effect estimates (Tables 5 and 6). The prospective cohort
study [66], enrolling 882 patients with one year follow-up,
found that two patients (2/438) in the basal insulin had
heart failure events and no patients (0/444) in exenatide
group. One retrospective cohort study [17], including
13,185 patients and with a median follow-up of four years,
reported that GLP-1 agonists were associated with a non-
significant increase in heart failure versus sulfonylureas
(adjusted HR 1.10, 95 % CI 0.99 to 1.22). The other retro-
spective cohort study [18], involving 39,225 patients and
with a median follow-up of 3.5 years, found that both exe-
natide and exenatide plus insulin were associated with a
lower risk of heart failure versus insulin alone (adjusted
HR 0.34, 95 % CI 0.22 to 0.52; adjusted HR 0.40, 95 % CI
0.32 to 0.50, respectively, Fig. 3). Using GRADE, we rated
the quality of evidence in the included studies as very low,
due to risk of bias, indirectness and heterogeneity in
addition to the inherent risk for confounding associated
with observational studies.
Studies reporting hospitalization for heart failure
One nested case–control study [19] assessed with GLP-1
agonists versus other oral anti-hyperglycemic drugs
Table 2 Intervention tested and event rates in randomized controlled trials
Study Medications used across groups Incretin Control Duration of
treatment
(weeks)
Type Events Type Events
Trials reporting heart failure
Inagaki 2012 [38, 39] BG or BG + TZD Exenatide 1/215 Insulin glargine 0/212 26
NCT00294723 2010 [40, 41] None Liraglutide 1/497 Glimepiride 0/248 104
NCT00318461 2010 [42–44] Metformin Liraglutide 1/724 Placebo 0/121 104
Liraglutide 1/724 Glimepiride 0/242
NCT00360334 2009 [45] OADs Exenatide 0/118 Insulin glargine 1/116 26
NCT00614120 2010 [46] Merformin Liraglutide 1/697 Glimepiride 0/231 16
NCT00701935 2013 [47] None Exenatide 0/43 Placebo 1/37 26
NCT00838903 2014 [48, 49] Metformin Albiglutide 2/302 Placebo 0/101 156
Albiglutide 2/302 Glimepiride 1/307
NCT00838916 2014 [50, 51] Metformin ± SU Albiglutide 2/504 Insulin glargine 2/241 156
NCT00839527 2014 [52] Metformin + glimepiride Albiglutide 0/271 Placebo 1/115 164
Albiglutide 0/271 Pioglitazone 4/277
NCT00849017 2014 [53] None Albiglutide 1/200 Placebo 2/101 164
NCT00849056 2014 [54] Pioglitazone ±Metformin Albiglutide 0/150 Placebo 1/151 156
NCT00855439 2015 [55] Other diabetes medications Exenatide 1/22 Glargine 1/24 78
NCT00960661 2013 [56, 57] Insulin glargine +metformin Exenatide 0/315 Insulin lispro 1/312 30
NCT01064687 2015 [58] Metformin and pioglitazone Dulaglutide 1/559 Placebo 0/141 26
Exenatide 0/278 Placebo 0/141
NCT01075282 2015 [59] Metformin and glimepiride Dulaglutide 3/545 Insulin glargine 1/262 78
NCT01126580 2015 [60, 61] None Dulaglutide 1/539 Metformin 0/268 52
NCT01191268 2014 [62] Insulin lispro Dulaglutide 0/588 Insulin glargine 1/296 52
NCT01512108 2014 [63] None Liraglutide 1/240 Additional OAD 0/120 52
NCT01620489 2014 [64] OAD and/or insulin Liraglutide 1/140 Placebo 0/137 26
Pratley 2013 [65] SU ±metformin Taspoglutide 0/494 Pioglitazone 2/257 24
Trials reporting hospitalization for heart failure
Bentley-Lewis 2015 (ELIXA) [15, 16] Metformin, SU, glinide, TZD, insulin,
metformin and SU, insulin and OADs,
or other diabetes medications
Lixisenatide 122/3034 Placebo 127/3034 100
BG biguanide, TZD thiazolidinedione, OADs oral antidiabetic drugs, SU sulfonylurea
Li et al. BMC Cardiovascular Disorders  (2016) 16:91 Page 6 of 14
(Tables 4 and 5). This study included 57,737 patients,
with a mean age of 61.6 years and mean duration of dia-
betes 2.3 years. The methodological details regarding the
control for bias are provided in Additional file 8. This
study included 1118 cases and 17,626 matched controls
and found that, compared to the use of other anti-
hyperglycemic drugs, GLP-1agonists were not associated
with increased risk of hospitalization for congestive
heart failure (adjusted OR 0.67, 95 % CI 0.32 to 1.42).
Using GRADE, we rated the quality of evidence as very
low, due to risk of bias and imprecision in addition to
the inherent risk for confounding associated with obser-
vational studies.
Discussion
Main findings
Our pooled analysis of 20 RCTs addressing use of GLP-1
agonists for type 2 diabetes found moderate quality evi-
dence suggesting no increase in heart failure. The only
RCT provided high quality evidence that lixisenatide did
not increase the risk of hospitalization due to heart fail-
ure. Though the four observational studies provide only
very low quality evidence, their results are consistent
with those from the randomized trials.
Strengths and limitations
We are the first to systematically review the evidence re-
garding GLP-1 agonists for type 2 diabetes and risk of
heart failure. Our study has several strengths. First, we
used rigorous methods to systematically identify both
randomized and observational studies that reported data
to inform this issue, including a large number of trials
that were not published in journals. Second, we carefully
checked the data reported in ClinicalTrials.gov and jour-
nal publications for consistency to ensure accuracy of
the data. Third, we analysed the data on heart failure
and hospitalization for heart failure separately, because
those outcomes are likely to be of different importance
to patients. Fourth, we used the GRADE approach to as-
sess the quality of evidence on an outcome-by-outcome
basis.
Our study also has limitations. First, the available evi-
dence is not strength to give definitive answer for this
question, since the included RCTs reported few heart
failure events and the follow-up was not enough for
heart failure to occur, and much findings came from ob-
servational studies of very low quality evidence. Second,
we have included some observational studies at moder-
ate to high risk of bias. This has made the inference
about the effects of GLP-1 agonists challenging. Third,
the diversity of observational studies also made our ana-
lysis of the evidence difficult. One retrospective cohort
study [18], assessing exenatide and/or insulin on heart
failure outcome, included patients with heart failure at
baseline, and the proportion of patients with history of
heart failure was higher in the insulin group (3.2 %) than
in the exenatide group (1.7 %) and exenatide + insulin
group (2.4 %), which made the finding from this study
biased.
Other researches
Ours is the first systematic review addressing the impact
of GLP-1 agonists on heart failure. There is some evi-
dence from human studies that GLP-1 agonists might
provide protection against heart failure: preliminary
study [67] showed that GLP-1 treatment might have a
trend towards improvement of cardiac function in type 2
diabetes patients with stable heart failure; intrinsic GLP-
1 expression has been shown to compensatorily upregu-
late in patients with left heart failure [68]; and GLP-1
Fig. 2 Risk of heart failure in patients who received GLP-1 agonists versus control from randomized controlled trials
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Table 3 GRADE evidence profile of glucagon-like peptide-1 receptor agonists and risk of heart failure in type 2 diabetes
Quality assessment Summary of findings Quality of
evidence
Study event rates Relative risk
(95 % CI)
Anticipated absolute
effects (5-year time frame)
No of participants
(studies)
Follow-up time
Risk of bias Inconsistency Indirectness Imprecision Publication
bias
With control With GLP-1
agonists
Risk with
control
Risk difference with
GLP-1 agonists
(95 % CI)
Heart failure
11758
(20)
16-164 weeks
Serious
limitation due
to risk of
biasa
No serious
limitations
No serious
limitations
Serious limitation,
confidence interval
includes important
benefit and harm
Undetected 19/4317
(0.44 %)
17/7441
(0.23 %)
OR 0.62
(0.31 to 1.22)
50 per
1000b
19 fewer per 1000
(34 fewer to 11 more)
⊕⊕ ΟΟ
Low due to
risk of bias and
imprecision
Hospitalization for heart failure
6068
(1)
2.1 years
No serious
limitations
No serious
limitations
No serious
limitations
Serious limitation,
confidence interval
includes important
benefit and harm
Undetected 127/3034
4.2 %
122/3034
4 %
HR 0.96
(0.75 to 1.23)
100 per
1000c
4 fewer per 1000
(25 fewer to 23 more)
⊕⊕⊕Ο
Moderate due
to imprecision
GLP-1 glucagon-like peptide-1
aSeveral trials probably had risk of bias on random sequence generation, allocation concealment and blinding (Additional file 2), and the follow up (median of 52 weeks) was not long enough for heart failure to occur
in patients with low risk of cardiovascular disease
bBaseline risk estimate for heart failure in a 5-year time frame comes from the control arm of the cohort study we identified to best represent our target population (Kannan 2015 [17]), with 528 events of heart failure
in 13,185 participants (4.0 %) at four year follow up across control and intervention arm
cBaseline risk estimate for hospitalization for heart failure in 5-year time frame comes from the control arm of the only included ELIXA trial [16] we identified to best represent our target population with 127 events in
3034 participants (42 per 1000) over a 2.1 year follow up period, in the absence of observational studies providing more credible baseline risk estimates
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Table 4 Characteristics of included observational studies
Study Study design Data
source
Countries
involved
Funding Total
number
of
patients
Follow
up
(years)
Male
(n, %)
Mean
age
(years)
Mean BMI
(kg/m2)
Mean
HbA1c (%)
Mean FPG
(mmol/L)
Mean diabetes
duration (years)
CVD at baseline
Studies reporting heart failure
NCT01060059
2013 [66]
Prospective
cohort study
Real
world
data
Italy Private
for-profit
funding
882 1 493
(55.9)
62.5 NR 8.9 NR NR NR
Kannan 2015 [17]a Retrospective
cohort study
Electronic
health
records
U.S. No
funding
13,185 4b 7827
(54.6)
60.6 32.6c NR NR NR Included patients had
no history of CVD or
congestive heart failure
at baseline
Paul 2015 [18] Retrospective
cohort study
Claims
data
U.S. NR 39,225 3.5b 18093
(46.1)
58.2 35.3 7.9 NR 1.3 Included patients had
CVD or no CVD at
baseline
Studies reporting hospitalization for heart failure
Yu 2015 [19]a Nested case–
control study
Electronic
medical
records
UK Public
funding
57,737 NA 32795
(56.8)
61.6 NR NR NR 2.3 Included patients had
CVD or no CVD at
baseline
aThese two studies accessed incretin agents (both glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors) and the risk of heart failure, so the data above were the characteristics of total
patients included
BMI body mass index, FPG fasting plasma glucose, CVD cardiovascular disease, NR not reported, NA not applicable
bmedian follow-up (years);
cMedian BMI (kg/m2)
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Table 5 Exposures, outcomes, and results of observational studies
Study Exposure of
interest
Control group Number of
events or cases
Total number
of analyzed
patients
Adjusted estimates
(95 % CI)
Adjusted covariate
Studies reporting heart failure
Kannan 2015
[17]
GPL-1 agonists
(combined with
metformine)
Sulfonylureas
(combined with
metformine)
528a 13,185 (55,110
person years)a
HR 1.10 (0.99 to 1.22) Age, sex, race, BMI, number of
encounters, median household
income, smoking status, systolic
and diastolic blood pressure,
hypertension, dyslipidemia,
cerebral vascular event,
presence of neuropathy,
retinopathy, dementia, chronic
obstructive pulmonary disease,
cancer, atrial fibrillation, anti-
hypertensive medications, lipid
lowering agents, anti-platelet
agents and propensity for being
on metformin and sulfonylureas
at baseline, lipid profile, esti-
mated glomerular filtration rate
Paul 2015
[18]
Exenatide/
exenatide
+ insulin
Insulin 2338 39,225 Exenatide vs insulin:
HR 0.34 (0.22, 0.52)
Exenatide + insulin vs insulin:
HR 0.40 (0.32, 0.50)
Without previous CVD:
Exenatide vs insulin:
HR 0.34 (0.22, 0.52)
Exenatide + insulin vs insulin:
HR 0.40 (0.32, 0.50)
Without previous CVD
& renal diseases:
Exenatide vs insulin:
HR 0.32 (0.21, 0.50)
Exenatide + insulin vs insulin:
HR 0.35 (0.28, 0.45)
Gender, ethnicity, age at the
start of cohort, BMI, HbA1c,
systolic and diastolic blood
pressure on the index date,
history of cardiovascular disease,
any renal disease prior to index
date or during follow-up, use of
metformin, sulfonylurea, cardio-
protective medications or anti-
hypertensive medications, and
the duration of diabetes
NCT01060059
2013 [66]
Exenatide Basal insulin 2 882 NR NR
Studies reporting hospitalization for heart failure
Yu 2015 [19] GLP-1 agonists
(exenatide and
liraglutide, alone
or incombination
with other
antidiabetic drugs)
Other oral
antidiabetic
drugs
1,118a 18,744a OR 0.67 (0.32 to 1.42) Sex, BMI, excessive alcohol use,
smoking status, HbA1c level,
comorbidities (neuropathy,
renal disease, retinopathy,
atrial fibrillation, cancer [other
than nonmelanoma skin
cancer], chronic obstructive
pulmonary disease, coronary
artery disease, dyslipidemia,
hypertension, previous
myocardial infarction, peripheral
arteriopathy, previous coronary
revascularization, peripheral
vascular disease, and previous
stroke), number of prescriptions,
number of physician visits, and
use of the following drugs in
the year prior to cohort entry:
angiotensin converting
enzyme inhibitors, angiotensin
receptor blockers, β-blockers,
calcium channel blockers,
diuretics, fibrates, statins, as-
pirin, and other nonsteroidal
anti-inflammatory drugs
aThese two studies accessed incretin agents and the risk of heart failure, and the data of events/cases and total number of analyzed patients regarding glucagon-like
peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors were not reported separately, so the data above were the data of total study patients
CI confidence interval, NR not reported, HR hazard ratio, OR odds ratio, CVD cardiovascular disease, BMI body mass index
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agonists are also shown to be associated with a modest in-
crease of ejection fraction in diabetic patients [69]. A recent
meta-analysis of RCTs [70] found that GLP-1 agonists were
associated with a modest reduction in blood pressure and a
slight increase in heart rate. These biological studies suggest
that GLP-1 agonists might, if anything, reduce the inci-
dence of heart failure. Though results of RCTs fail to show
this decrease, confidence intervals do not exclude the possi-
bility of a modest reduction.
Conclusions
The current evidence suggests that GLP-1 agonists do
not increase the risk of heart failure or hospitalization
for heart failure. The current body of evidence, however,
is not definitive. More carefully designed, conducted, ad-
equately powered trials and observational studies are
warranted to confirm the effects of GLP-1 agonists on
incidence of heart failure and hospitalization for heart
failure. Future studies should also examine whether the
Table 6 Risk of heart failure or hospitalization for heart failure among patients with type 2 diabetes receiving glucagon-like peptide-1
receptor agonists treatment
Comparison Number of studies
(Events or cases,
patients)
GLP-1 agonists
(events/patients)
Control
(events/
patients)
Effect Estimate
(95%CI)
Cardiovascular morbidities
at baseline
1. Heart failure
Randomized controlled trials
GLP-1 agonists vs. control 20 (36, 11758) 17/7441 19/4317 Pooled OR 0.62
(0.31 to 1.22)
Typically without CVD
at baseline
Cohort studies
GLP-1 agonists vs. SU 1 (528, 13185) NR NR Adjusted HR 1.10
(0.99 to 1.22)
No history of CVD or
congestive heart failure
at baseline
Exenatide vs. insulin
Exenatide + insulin vs. insulin
1 (2338, 39225) 49/2804
195/7870
2094/28551
2094/28551
Adjusted HR 0.34
(0.22, 0.52)
Adjusted HR 0.40
(0.32, 0.50)
With or without CVD
at baseline
Exenatide vs. basal insulin 1 (2, 882) 0/444 2/438 Unadjusted OR 0.13
(0.01 to 2.13)
NR
2. Hospitalization for heart failure
Randomized controlled trials
Lixisenatide vs. placebo 1 (249, 6068) 122/3034 127/3034 Pooled Adjusted HR
0.96 (0.75, 1.23)
Acute coronary syndrome
Nested case–control studies
GLP-1 agonists vs. other OADs 1 (1118, 18744) Adjusted OR 0.67
(0.32 to 1.42)
With or without CVD
at baseline
GLP-1 glucagon-like peptide-1, CVD cardiovascular disease, SU sulfonylurea, OR odds ratio, HR hazard ratio, NR not reported, OADs oral antidiabetic drugs
Fig. 3 Risk of heart failure in patients who received GLP-1 agonists versus control based on adjusted data of observational studies
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effects of GLP-1 agonists on heart failure are affected by
patient's baseline risk of cardiovascular disease.
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